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Method and evidence collection
Our search included studies regarding anesthesia, anesthe-
tics, strategy and anesthetic management (induction, main-
tenance, and adjuvants), cardiovascular support, mechanical 
ventilation, and monitoring, whether or not related to clinical 
outcome (mortality, length of stay, duration of mechanical 
ventilation, and vasopressor or inotropic support). We also 
selected articles on speciﬁ c drugs (etomidate, ketamine, 
corticosteroids, and others) and applied the following stra-
tegy using the PubMed system to search Medline database, 
with unlimited publication date:
“Sepsis” [Mesh] OR “Shock, Septic” [Mesh]) AND 
a. “Anesthesia” [Mesh] OR “Anesthesia, Inhalation” 
[Mesh] OR “Balanced Anesthesia” [Mesh] OR 
“Anesthesia, Intravenous” [Mesh] OR “Anesthesia, 
General” [Mesh] OR “Adjuvants, Anesthesia” [Mesh] 
OR “Anesthetics, Inhalation” [Mesh] OR “Anesthetics, 
General” [Mesh] OR “Anesthetics” [Mesh] OR 
”Anesthetics, Combined” [Mesh] OR ”Midazolam” 
[Mesh] OR “Ketamine” [Mesh] OR “Intraoperative 
Care” [Mesh] OR “Etomidate” [Mesh]);
b. “dopamine”, “noradrenaline”, “norepinephrine”, 
“vasopressor agent”, “outcome” and “mortality”;
c. “Fluid” [Mesh]) AND “colloids” [Mesh] OR “starch” 
[Mesh] OR “hypertonic solution” [Mesh] OR “saline” 
[Mesh];
d. “early goal direct therapy” OR “EGDT” AND 
(outcome)
e. “methylene blue” [Mesh];
f. “cardiac output” OR “cardiac index” OR “stroke 
volume variation” OR “pulse pressure variation”.
Level of evidence and grade of 
recommendation
The level of evidence (LE) and grade of recommendation 
(GR) of each study were assigned according to the Centre of 
Evidence Based Medicine (CEBM) classiﬁ cation.1
A. Experimental or observational studies of better con-
sistency, meta-analyses with randomized controlled 
trials homogeneity (LE = 1);
B. Experimental or observational studies with less con-
sistency (LE = 2 or 3) or extrapolations of studies (LE 
= 1);
C. Case report or series (non-controlled studies) (LE = 
4); or extrapolations of studies (LE = 2 or 3);
D. Opinion without critical evaluation, based on consen-
sus, expert opinions, physiological studies or animal 
models, meta-analyzes with high coefﬁ cient of hete-
rogeneity (LE = 5) or inconsistent or non-conclusive 
studies of any level.
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Introduction
Sepsis is the leading cause of death in the intensive care 
unit (ICU).2 However, there are few studies assessing the 
epidemiology of systemic inﬂ ammatory response syndrome 
(SIRS), sepsis, severe sepsis, and septic shock, according 
to the American College of Clinical Pharmacy (ACCP) and 
Society of Critical Care Medicine (SCCM) consensus criteria.3 
Throughout the present investigation, we identiﬁ ed some 
studies demonstrating the increased incidence4 (8.7%/year)5 
and only a small reduction in mortality.4 Mortality rate in 
the United States was 27.8% in the late 1970s versus 17.9% 
in 2000.5 A study estimated the annual incidence of 3:1,000 
sepsis cases in the United States,6 with an annual growth of 
1.5%/year and overall mortality of 28.6%. A European study7 
of patients with septic shock also found increased incidence 
of 7 to 9.7 of 100 admissions and mortality reduction from 
62.1% to 55.9% between 1993 and 2000. In Brazil, according 
to DataSUS,8 there were 232,679 hospitalizations between 
January 2008 and August 2012, with the international code 
of diseases 10th version (ICD-10): septicemia. Mean hospital 
stay was 11.6 days, with 121,103 deaths (52.5%). According 
to the study Bases,9 the ﬁ rst prospective epidemiological 
cohort of sepsis in a developing country, which included 
1,383 patients hospitalized in ﬁ ve intensive care units, the 
incidence-density of sepsis was 57.9 (95% CI: 51.5-65.3) 
per 1,000 patients.day.-1 Mortality rates attributed to SIRS, 
sepsis, severe sepsis, and septic shock were 24.2%, 33.9%, 
46.9%, and 52.2%, respectively. The Sequential Organ Failure 
Assessment (SOFA) maximum scores for sepsis, severe sepsis, 
and septic shock were 5, 8.8, and 11, respectively. Most sepsis 
diagnoses of (67.7%) were made during admission of patients 
to the ICU and the remaining 32.3% in the following days. 
The study also showed that the incidence of severe sepsis 
and mortality at intensive care units of public hospitals is 
higher than at private hospitals (16% versus 35% and 28.9% 
versus 12.5%; p < 0.005).
One multicenter prospective cohort study,10 which in-
cluded 3,128 patients admitted to 75 ICUs in 65 Brazilian 
hospitals, found 16.7% incidence of sepsis, severe sepsis or 
septic shock. Mortality rates for sepsis, severe sepsis, septic 
shock, and overall mortality in 28-day were estimated at 
16.7%, 34.4%, 65.3%, and 46.6%, respectively. The average 
length of stay in the ICU was 15 days. 
Finally, another prospective, multicenter and observatio-
nal study,2 with 560 patients admitted to three ICUs, found 
sepsis, severe sepsis, and septic shock incidences of 31.9%, 
24.4%, and 31.4%, respectively, and mortality rates of 10.1%, 
22.6%, and 64.8%, respectively.
Septic patients are often undergoing urgent or emergency 
surgical procedures and, necessarily, an anesthesiologist sees 
these patients.
The anesthesiologist is a professional whose training gives 
him skills for rapid management of critical conditions. The 
knowledge of physiology and pathophysiology of the various 
organ systems makes him able to meet the multifaceted 
therapeutic challenge of sepsis, surgery, and anesthesia.11
The anesthesiologist priority is to improve the patient’s 
condition to get maximum beneﬁ t from the surgical proce-
dure and achieve short-term survival.12 Therefore, predic-
ting a greater susceptibility of these patients to anesthetic 
drugs is fundamental. Another key point is the management 
of hemodynamic and respiratory variables affected by the 
sepsis process and worsened by surgery, anesthesia, blee-
ding, loss of ﬂ uid, hypothermia, and other critical events. 
Anesthesiologists need to apply their knowledge to predict 
the pharmacodynamic and pharmacokinetic behavior in 
septic patients, with varying degrees of organ dysfunction, 
such as increased extravascular space, hypoalbuminemia, 
and increased levels of acid glycoprotein (AGP).13
Objective
Several clinical predictors and organ dysfunction scores 
were created to aid the physician in assessing the degree 
of severity, risk and prognosis in the short and long term 
such as Multiple Organ Dysfunction Score (MODS), Logistic 
Organ Dysfunction Score (LODS), Sequential Organ Failure 
Assessment (SOFA); cytokine levels, and various sepsis se-
verity assessment score such as Mortality Probability Model 
Score (MPMS), Simpliﬁ ed Acute Physiology Score II (SAPS II), 
Acute Physiology and Chronic Health Disease Classiﬁ cation 
(Apache II and III). In this study, we have given utmost impor-
tance to indicators of short-term outcome, due to the short 
time the anesthesiologist spends with the septic patient. 
The morbidity and mortality indicators chosen by clinical 
trials are reported by the articles of greatest impact (days 
of hospitalization and mechanical ventilation and 28-day 
mortality) and repeated in less impact articles, in order to 
better compare data obtained.
Based on the best current evidence (2012) resulting from 
qualitative systematic review, this recommendation aims to 
answer the following clinical questions:
1. Does the use of etomidate as an induction agent 
increase the morbidity and mortality indicators in 
septic patients undergoing tracheal intubation?
2. Is midazolam superior to etomidate regarding mor-
bidity and mortality indicators in septic patients 
undergoing tracheal intubation induction?
3. Is ketamine superior to etomidate regarding morbidi-
ty and mortality rates in septic patients undergoing 
tracheal intubation induction?
4. Is cardiovascular support with norepinephrine superior 
to dopamine regarding septic patient’s morbidity and 
mortality?
5. Is cardiovascular support with the combination of no-
repinephrine and dobutamine superior to epinephrine 
regarding septic patient’s morbidity and mortality?
6. Is cardiovascular support with phenylephrine superior 
to norepinephrine regarding septic patient’s morbidity 
and mortality?
7. Is there beneﬁ t in the use of methylene blue regar-
ding morbidity and mortality indicators in septic 
patients?
8. Is there a difference between volatile and intrave-
nous anesthetics for general anesthesia maintenance 
regarding mortality in septic patients?
9. Is there inﬂ uence on MAC Values of inhaled anesthetics 
in septic patients?
10. Is ﬂ uid resuscitation with albumin superior to crys-
talloid infusion regarding morbidity and mortality 
indicators in septic patients?
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11. Is volume replacement with hydroxyethyl starch su-
perior to crystalloid infusion regarding morbidity and 
mortality indicators in septic patients?
12. Is hypertonic saline infusion superior to normal saline 
regarding morbidity and mortality indicators in septic 
patients?
13. Is the early goal-directed therapy implementation 
superior to other approaches of septic patients?
14. Is cardiac output monitoring by uncalibrated pulse 
power analysis accurate in septic patients?
Does the use of etomidate as an induction 
agent increase the morbidity and mortality 
indicators in septic patients undergoing 
tracheal intubation?
A retrospective cohort study (B)14 that included 224 patients 
with severe sepsis or septic shock compared tracheal intuba-
tion performed after hypnotic induction with etomidate or 
other drugs. Apache II, MPM II, vasopressors, corticosteroids, 
and adrenal suppression were measured (assessed by tests 
of cortisol alone or corticotropin test). 
Among patients who received etomidate, the relative 
risk for mortality, use of vasopressors and corticosteroids 
were: a) relative risk (RR): 0.92, CI: 0.74-1.14, p = 0.51; b) 
RR: 1.16, CI: 0.9-1.51, p = 0.31; and c) RR: 1.34, CI: 1.11-
1.61, p = 0.003.
There was no statistically signiﬁ cant difference in the 
outcomes: length of ICU stay (days), mechanical ventilation 
(days), APACHE II, and MPM II.
A meta-analysis (D)15 compared the effects of a single 
dose of etomidate with other agents in critically ill patients. 
Mortality rate at 28 days (primary outcome) and incidence 
of adrenal insufﬁ ciency (secondary endpoint assessed by the 
corticotrophin or serum cortisol test) were recorded. The 
28-day mortality outcomes and adrenal insufﬁ ciency were: 
a) RR: 1.19; extreme 1.10-1.30, n = 3,516, p = 0.0001; coe-
fﬁ cient of heterogeneity (I2) = 64% (values greater than 30% 
indicate heterogeneity of studies); and b) RR: 1.64, extre-
mes: 1.52-1.77, n = 2,854, p = 0.0001; I2 = 88%. A reanalysis 
including only septic patients (n = 1,767) showed the same 
trend (RR: 1.22, extremes: 1.11-1.35; I2 = 74%, p = 0.0001), 
but not non-septic patients (RR: 1.15, extremes: 0.97-1.35, n 
= 1,749, I2 = 53%, p = 0.1). The study also found that cortisol 
levels of patients exposed to etomidate were 50% lower than 
in non-exposed patients and adrenal suppression persisted 
for 12 to 24 hours after single injection.
Another systematic review with meta-analysis (A)16 of 
randomized controlled and observational trials of patients 
with severe sepsis or septic shock evaluated mortality and 
adrenal suppression (by corticotropin test) after a dose of 
etomidate for rapid sequence intubation. Relative risk for 
overall mortality, mortality in randomized controlled trials, 
and at 28 days were respectively: a) RR: 1.20, 95% CI: 1.02-
1.42; Q: 20, I2 = 4, 9%, n = 865; b) RR: 1.26, 95% CI: 1.06-
1.50; Q: 3.39, I2: 11.6%, n = 795; and c) RR: 1.28, 95% CI: 
1.06-1.54; Q: 3.70; I2: 46%. Relative risks for general adrenal 
insufﬁ ciency and in randomized controlled trials were: a) RR: 
1.33, 95% CI: 1.22-1.46; Q: 10.7; I2: 43.9%; n = 1,303, and b) 
RR 1.35, 95% CI: 1.24-1.47; Q: 1.24; I2: 0%.
Recommendations: The use of etomidate for septic patients 
tracheal intubation was associated with adrenal suppression 
(A) persisting for 12 to 24 hours after administration (D), 
increased mortality (A), and corticosteroids consumption 
(B). 
Therefore, etomidate is contraindicated for tracheal 
intubation in patients with sepsis.
Is midazolam superior to etomidate regarding 
morbidity and mortality rates in septic 
patients undergoing tracheal intubation 
induction?
Another prospective, double-blind, randomized study (A)17 
compared etomidate and midazolam as induction agents for 
endotracheal intubation of 122 patients with a presumptive 
diagnosis of sepsis in the intensive care unit. No difference 
was found between midazolam and etomidate groups in 
the following outcomes: mean time of hospital stay (9.5 
versus 7.3 days), ICU stay (4.2 versus 3.1 days), and on 
mechanical ventilation (2.8 versus 2.1 days). Mortality was 
assessed as a secondary outcome and there was no signiﬁ cant 
difference.
Recommendations: There is no evidence in the literature 
reporting differences between length of hospital or ICU stay, 
duration of mechanical ventilation, and mortality between 
the use of midazolam or etomidate for intubation in patients 
with severe sepsis or septic shock (A).
Midazolam is recommended as an alternative to etomi-
date as hypnotic agent for tracheal intubation in patients 
with a presumptive diagnosis of sepsis.
Is ketamine superior to etomidate regarding 
morbidity and mortality indicators in septic 
patients undergoing tracheal intubation 
induction?
A multicenter prospective, randomized, blinded controlled 
study (A)18 involving 469 patients (180 with sepsis) compared 
the use of etomidate or ketamine (single dose) for tracheal 
intubation. The primary endpoint was the maximum SOFA 
index in the ﬁ rst three days. Secondary endpoints were: 
SOFA index variation, mortality, days out of intensive care, 
and days without mechanical ventilation or vasoactive drugs 
in the following 28 days. In the septic group with patients 
exposed to etomidate or ketamine, the mean maximum SOFA 
index was respectively: 12.4 (SD: 3.8) and 10.8 (SD: 4.5), with 
an absolute difference of 1.6 (95% CI: -0.3-3.4), and mortality 
(OR: 0.8, 95% CI: 0.5-3.5). The other endpoints showed no 
difference with respect to exposure to ketamine or etomida-
te. Adrenal suppression was assessed by corticotropin test, 
and etomidate group was associated with a higher incidence 
of adrenal suppression (OR: 6.7, 95% CI 3.5-12.7, p = 0.01).
Recommendations: Ketamine is associated with similar 
mortality rates and lower incidence of adrenal suppression 
compared to etomidate for intubation of patients with 
sepsis (A).
Ketamine is recommended as an alternative to etomidate 
for intubation of patients with sepsis.
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Is cardiovascular support with norepinephrine 
superior to dopamine regarding septic 
patient’s morbidity and mortality?
A systematic review (A)19 of observational (n = 1,360) and 
randomized (n = 1,408) articles compared the use of no-
repinephrine or dopamine in patients with septic shock. 
Observation group (after the exclusion of one study, which 
improved the homogeneity of the population) and randomi-
zed group showed signiﬁ cant increase in 28-day mortality 
with the use of dopamine (RR: 1.23, 95% CI: 1,05-1.43, p < 
0.01; I2 = 32.3% and RR: 1.12, 95% CI: 1.01-1.20, p < 0.35; 
I2 = 0%, respectively). In two of the interventional studies, 
dopamine has been linked with increased risk of arrhythmias 
(RR: 2.34, 95% CI: 1.46-3.77, p = 0.001).
These results are in line with another systematic review 
of randomized trials20 with 2,043 patients in which norepine-
phrine was superior to dopamine regarding 28-day mortality 
(RR: 0.91, 95% CI: 0.83-0.99; p = 0.028, I2 = 0.0%).
Recommendations: Norepinephrine is associated with lower 
incidence of arrhythmia and mortality compared to dopamine 
for hemodynamic support of septic patients.
Noradrenaline is recommended as the agent of choice for 
hemodynamic support of septic patients (A).
Is cardiovascular support with the 
combination of norepinephrine-dobutamine 
superior to epinephrine regarding septic 
patient’s morbidity and mortality?
A prospective, multicenter, randomized, double-blind 
study21 with 330 adults admitted to the ICU compared the 
combination of norepinephrine and dobutamine with epi-
nephrine. The primary endpoint was 28-day mortality. The 
secondary endpoints were mortality at 7 and 14 days, up to 
ICU and hospital discharge, survival at 90 days, hemodynamic 
parameters, arterial pH and lactate, SOFA score, time to 
successful hemodynamic stabilization, and time to weaning 
of vasoactive drugs. The result was not signiﬁ cant for 28-
day mortality (RR: 0.86, 95% CI: 0.65-1.14), or for the other 
secondary endpoints, except for pH (p = 0.01) and lactate 
(p = 0.001) being higher in the adrenaline group.
Recommendations: There is no evidence of a statistically 
signiﬁ cant difference in mortality outcomes, duration of 
vasopressor support, and 90-day survival with the use of 
norepinephrine-dobutamine compared with adrenaline (A). 
However, the levels of lactate are signiﬁ cantly higher and 
pH is signiﬁ cantly lower in patients treated with adrenaline 
(A).
The combined use of dobutamine and norepinephrine is 
recommended for hemodynamic support of septic patients, 
when indicated.
Is cardiovascular support with phenylephrine 
superior to norepinephrine regarding septic 
patient’s morbidity and mortality?
A prospective, randomized controlled study22 compared 
equipotent doses of phenylephrine and noradrenaline for 
hemodynamic support of 32 patients with septic shock. There 
were no statistically signiﬁ cant differences in the primary 
endpoint mortality (RR: 1.11, 95% CI: 0.63-1.97) and secon-
dary endpoints: systolic volume index (49 ± 19, 50 ± 11, p = 
0.963), pH (7.37 ± 0.08, 7.34 ± 0.08, p = 0.435), base excess 
(0.2 ± 6.3, -3.0 ± 6.4, p = 0.228), mixed venous saturation 
(67 ± 9, 67 ± 10, p = 0.431), and length of ICU stay (16 days, 
extreme: 7-25; 16 days, extreme: 10-24). 
Recommendations: The only level-1 evidence study com-
paring norepinephrine and phenylephrine for hemodynamic 
support of septic patients found no difference between 
norepinephrine and phenylephrine regarding mortality and 
hemodynamic and metabolic indices (A). However, because 
the study involved a small sample size in order to detect 
differences equal to or greater than 30%, the choice of nore-
pinephrine is recommended due to the already demonstrated 
advantages over other vasopressors.
Is there beneﬁ t in the use of methylene blue 
regarding morbidity and mortality indicators 
in septic patients?
A qualitative systematic review23 assessed the use of me-
thylene blue associated with vasoactive drugs in septic 
shock treatment. It included 14 studies (2 prospective and 
randomized studies). Meta-analysis was not possible due to 
the great heterogeneity. The study concluded that the use 
of methylene blue signiﬁ cantly reduced the need for nore-
pinephrine (87%), epinephrine (81%), and dopamine (40%), 
in addition to being associated with increased peripheral 
and pulmonary vascular resistance. Heterogeneity of studies 
prevented conclusions about mortality. Survival at 28 days 
was 50% in the methylene blue group and 30% in the control 
group; however, without statistical signiﬁ cance.
Recommendations: Methylene blue is associated with in-
creased systemic vascular resistance and blood pressure, 
without evidence of improving oxygen delivery to tissue or 
death (D).
Until there is better evidence, methylene blue should 
not be used as an adjuvant for hemodynamic support of 
patients with sepsis.
Is there a difference between volatile and 
intravenous anesthetics for general anesthesia 
maintenance regarding septic patients’ 
morbidity and mortality? 
In animal models, volatile anesthetics have anti-inﬂ ammatory 
properties and reduce oxidative stress, lipid peroxidation, 
and inﬂ ammatory response. This effect is more marked 
with sevoﬂ urane compared to isoﬂ urane. There is also evi-
dence that sevoﬂ urane is associated with lower mortality 
rates compared to isoﬂ urane.24 In the animal sepsis model, 
isoﬂ urane for maintenance of general anesthesia provides 
increased survival and reduced pulmonary injury and inﬂ am-
matory reaction compared to pentobarbital,25,26 in addition 
to being related to renal, hepatic, and anti-inﬂ ammatory 
effect protection and mortality reduction (D).27 On the other 
hand, there is evidence that isoﬂ urane may trigger delete-
rious effects on the endocrine-metabolic response in animal 
models of sepsis, with increased lung and inﬂ ammatory 
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cascade injury, compared to animals not submitted to anes-
thesia (D).28 In animal model of sepsis, comparison between 
ketamine, alfentanil, isoﬂ urane, and halothane showed that 
ketamine is associated with better laboratory, metabolic, and 
hemodynamic proﬁ les, compared with the other agents. In 
this study, halothane, compared with the other agents, was 
related to the worse laboratory and metabolic hemodynamic 
proﬁ les (D).29 There is also evidence from studies in animal 
models of sepsis that compared with propofol, isoﬂ urane has 
protective lung effects according to histological criteria and 
capillary permeability tests (D).30
Recommendations: There is no evidence of any agent supe-
riority for maintenance of anesthesia in humans. Considering 
that animal studies have no sufﬁ cient level of evidence for a 
recommendation, it is concluded that there is no scientiﬁ c 
support for recommending the use of anesthetics for main-
tenance of general anesthesia in patients with sepsis (D).
Is there inﬂ uence on MAC values of inhaled 
anesthetics in septic patients?
A study (D)31 evaluated the effect of septic status on the MAC 
of isoﬂ urane in rodent model of sepsis. The isoﬂ urane MAC 
in normotensive rats was estimated at 0.81% (SD = 0.3%) in 
the group of rats subjected to sepsis and 1.4% (SD: 0.12%) in 
the control group (p < 0.003). Secondary endpoints showed 
no signiﬁ cant differences: heart rate, blood pressure, except 
metabolic acidosis (pH of control group: 7.35; SD: 0.02 and pH 
of septic group: 7.28; SD = 0.02; p < 0.05). In another study 
(D),32 the MAC of sevoﬂ urane in normotensive pigs was esti-
mated at 1.35% (95% CI: 1.2-1.45, p < 0.05) for septic group 
and 2,4% (95% CI: 2.1-2.55, p < 0.05) for control group.
Recommendations: Although evidence suggest that the MAC 
of inhalational anesthetics is lower in septic animals than in 
non-septic animals, it is not possible to extrapolate these 
results to humans (D).
Is ﬂ uid resuscitation with albumin superior to 
crystalloid infusion regarding morbidity and 
mortality indicators in septic patients?
A systematic review with meta-analysis (A),33 which included 
1,977 adult and pediatric patients with severe sepsis or septic 
shock (Safe test subgroup), compared the mortality outcome 
between groups receiving solutions containing albumin and 
groups receiving other solutions for parenteral hydration. The 
authors concluded that in septic patients albumin replace-
ment is associated with lower mortality rates (OR: 0.82; 95% 
CI: 0.67-1; I2: 0%; p < 0.047). However, data re-evaluation 
according to a random-effects model showed that effects are 
not signiﬁ cant on mortality (OR: 0.84; 95% CI: 0.69-1.02; p = 
0.08), and the reviewed articles reporting albumin beneﬁ ts 
were those comparing it with crystalloids (1,441 patients, 
OR: 0.78; 95% CI: 0.62-0.99; p = 0.04) (A).34
Another meta-analysis (A)35 compared several strategies 
for volume replacement in a population of critically ill 
pediatric and adult patients from different causes (burns, 
sepsis, trauma). A sub-analysis of 7,754 patients undergoing 
replacement with albumin or plasma compared with crys-
talloid found no signiﬁ cant difference (RR: 1.01; 95% CI 
0.92-1.10; p = 0.87).
Recommendations: There is no evidence that volume re-
placement with albumin is superior to crystalloids in septic 
patients (A).
Is volume replacement with hydroxyethyl 
starch superior to crystalloid infusion 
regarding morbidity and mortality indicators 
in septic patients?
In a prospective, multicenter, controlled, randomized, 
double-blind study (A)36 (Scandinavian starch for severe 
sepsis/septic shock - 6S), 6% hydroxyethyl starch infusion 
(HES 130/0.42) was compared with Ringer’s lactate infusion 
up to 33 mL.kg-1 in 798 patients with septic shock. The pri-
mary endpoints analyzed were mortality and terminal renal 
injury (dialysis-dependence), both at 90 days. The results 
found were mortality (HES/Ringer: RR: 1.17; 95% CI: 1.01-
1.36; p = 0.03) and one patient in each group progressed to 
end-stage renal failure. Secondary endpoints were need for 
renal replacement therapy during intensive care stay (RR: 
1.35; 95% CI: 1.01-1.80; p = 0.04) and severe bleeding (RR: 
1.52; 95% CI: 0.94-2.48; p = 0.09).
Another multicenter study (VISEP) (A)37 included 537 
randomized patients with severe sepsis for intensive or 
conventional interventions with insulin therapy and volu-
me replacement with 10% HES 200/0.5 or Ringer’s lactate. 
The study was stopped early for safety reasons (nocturnal 
hypoglycemia in the intensive insulin group). The primary 
endpoints were mortality and SOFA index. The secondary 
endpoints were acute renal failure (baseline creatinine in-
creased by 100%), length of hospital stay, time on mechanical 
ventilation, blood transfusion, hemodynamic stabilization, 
vasopressor use, and mortality at 90 days. There was no 
difference between HES and Ringer’s groups regarding 
mortality rates (26.7% and 24.1%; p = 0.48), but there was 
a trend towards increased 90-day mortality (41% and 33.9%; 
p = 0.09). There was no difference in mean SOFA index (8 
and 7.5, p = 0.16). There was an increase in the incidence 
of acute renal failure (34.9% versus 22.8%; OR: 1.81; 95% CI: 
1.22-2.71; p = 0.002)38 and more days on renal replacement 
therapy (18.3% versus 9.2%). After multivariate analysis of 
subgroups, researchers found increased 90-day mortality in 
subgroup receiving high dose of HES compared with the low-
dose group (57.6% versus 30.9%; OR: 3.08; 95 %: 1.78-5.37; 
p = 0.001) (A)38 and increased 90-day renal failure and need 
for renal replacement therapy in HES group with low-dose 
compared with Ringer’s group (30.9% vs 21.7%; p = 0.04 and 
25.9% vs 17.3%; p = 0.03). Patients in HES group received 
less volume (p < 0.04) and more rapidly achieved CVP over 
8 (p < 0.008).
Recommendations: There are evidences that starch solution 
infusion of various molecular weights is associated, in a dose-
dependent manner, with a higher incidence of renal injury 
compared to Ringer’s lactate. Given the positive aspects of 
starch solution administration, including the lowest amount 
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needed to maintain intravascular volume and more rapid ﬂ uid 
resuscitation, monitoring renal function when using these 
agents in patients with sepsis is recommended (A).
Is hypertonic saline infusion superior to 
normal saline regarding morbidity and 
mortality indicators in septic patients?
A prospective, controlled, randomized, and double-blind 
study39 with 24 adults in intensive care compared isotonic and 
hypertonic saline solution infusions. Patients were monitored 
with PiCCO (Pulse Contour Cardiac Output Monitoring) and 
gastric tonometry. Treatment group received 250 mL solution 
of 6% HES/200 in 7.2% sodium chloride and control group re-
ceived 500 mL solution of 6% HES/200 in 0.9% sodium chloride. 
The primary endpoint was gastric tonometry and secondary 
endpoints were mean blood pressure (MAP), noradrenaline in-
fusion, central venous pressure (CVP), cardiac index (CI), CO, 
stroke volume variation (SVV), intrathoracic blood volume 
index (ITBVI), and diuresis. Among hemodynamic parameters, 
there was no statistically signiﬁ cant difference for ITBVI, 
SVV, CVP, and CI. Norepinephrine infusion rate was lower in 
treatment group (p < 0.008), as well as the infusion volume 
(hypertonic: 2.8; SD: 1.5 L/24h, isotonic: 4.1, SD: 1.6 L/24h, 
p = 0.46); diuresis was higher in treatment group (p = 0.19). 
Among cardiac effects; contractility was higher in treatment 
group with increased blood volume index (BVI) (p = 0.0012). 
Gastric tonometry showed hypoperfusion in both groups (p = 
0.17), without signiﬁ cant differences between groups after 
volume infusion (p = 0.31), as there was no difference in CO2 
between ﬂ uid responsive and non-responsive patients (p = 
0.64). The evaluation of sublingual microcirculation showed 
no difference between treatment and control groups, in whi-
ch the comparison of initial parameters showed difference 
only for ﬂ uid responsive patients in each group (baseline: 
2.32; IQR: 1.63 to 2.79; after treatment: 2.90; IQR: 2.43 to 
2.98, p = 0.04). Among metabolic parameters, lactate levels 
were higher in treatment group before (p = 0.09) and after 
infusion (p = 0.04). Sodium and chloride levels become higher 
in treatment group 30 minutes after infusion, but without 
affecting pH levels.
Recommendation: There is evidence that infusion of 6% 
HES/200 with 7.2% sodium chloride is associated (in metabo-
lism and lingual microcirculation) with increased myocardial 
contractility and other hemodynamic variables, regardless of 
the positive effect on plasma expansion; however, without 
demonstrating superiority to isotonic solution.
Is the implementation of early goal-directed 
therapy superior to other approaches in 
septic patients?
A qualitative systematic review (D)40 assessed the impact 
evidence of the early goal-directed therapy (EGDT) imple-
mentation. This review recorded 5,998 patients with severe 
sepsis or septic shock (3,042 before and 2,956 after EGDT im-
plementation). There was no difference in sex, age, APACHE 
II, and mortality parameters of the studied population. Mean 
relative risk reduction (RRR) and absolute risk reduction 
(ARR) were 26% ± 0.46 and 20.3 ± 12.7%, respectively. These 
data were superior to the original 2001, which found 34% and 
16%, respectively. This review also identiﬁ ed a decrease in 
hospital costs and hospital stay (up to 23.4%, four days or 
32.4%; p = 0.03 in one study).
In another review by the same author (D),41 the impact 
of EGDT implementation was evaluated 10 years after the 
classic study publication in 2001.42 The revised population 
comprised 19,411 patients with severe sepsis or septic shock 
(9,527 before and 9,884 after EGDT implementation). APACHE 
II score was comparable between groups, but higher than 
that of the classic study. The conclusions also differed from 
those in the 2001 article, with a RRR of 0.37 and ARR of 18.3% 
and a reduction of 20% in hospital costs, mainly because of 
shorter ICU stay (ﬁ ve days per patient).
Recommendations: There are evidences that in septic pa-
tients the early goal-directed therapy approach is associated 
with lower mortality, shorter hospital stay, and reduced 
hospital costs compared with other ﬂ uid resuscitation ap-
proaches. However, this evidence was derived from reviews 
that were not systematic or meta-analytic, not indicating 
the degree of heterogeneity between studies, albeit provi-
ding cumulative analysis, which included the reduction of 
absolute and relative risk based on results from prospective 
randomized clinical trials. 
The authors recommended that EGDT be used as a strate-
gy for early ﬂ uid resuscitation of patients with severe sepsis 
or septic shock (D).
Is cardiac output monitoring by uncalibrated 
pulse power analysis accurate in septic 
patients? 
A study (B)43 including 24 septic patients compared the mea-
surements of cardiac output by pulse wave analysis systems 
(FloTrac/Vigileo, 1.07) and transpulmonary thermodilution 
(PiCCO plus) before and after the increased MAP with norepi-
nephrine infusion. There was signiﬁ cant correlation between 
measurements.
Another study (B)44 compared the newest version (3:02) 
of the FloTrac/Vigileo system with thermodilution system 
before and after volume expansion and increasing or reducing 
the dose of norepinephrine in 60 patients (48 septic). The 
coefﬁ cients of determination r2: 0.26, 0.0025, 0.16; measu-
re of bias 0.11, 0.36, 0.17; and limits of agreement -1.2 to 
0.98, -1.25 to 1.98, -1.26 to 0.92 found for the three study 
procedures, respectively, indicate that the third generation 
FloTrac system was not reliable in detecting changes in CO 
induced by norepinephrine, not even by volume expansion, 
and that the higher the systemic vascular resistance the 
greater the bias.
Another study (1B)45 compared estimates of cardiac 
index by uncalibrated pulse wave analysis (FloTrac) or 
thermodilution-calibrated pulse contour analysis (PiCCO) 
in 80 septic patients undergoing interventions with volume 
expansion or norepinephrine dose introduction/increase. The 
respective results were: a) CI bias: -0.23 ± 0.95 L.min.-1m-2, 
-0.01 ± 1.75 L.min.-1.m-2; b) percentage variation: r = 0.33 
(p < 0.05), -0.03 (p = 0.65); c) ability to detect CI increase 
> 15% by thermodilution: 56% sensitivity and 71% speciﬁ city; 
23% sensitivity and 96% speciﬁ city. These results repeat the 
previous study ﬁ ndings.44 
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Another prospective, observational, multicenter study 
(1B)46 involving 58 septic patients compared the thermo-
dilution method (TD) in pulmonary artery with the FloTrac 
algorithm second and third generation (G2, and G3, respec-
tively). The results found for CI in the comparison were: a) 
mean bias with 95% CI: -10 (-15 to -5)% [-0.8 (-1.1 to - 0.4) 
L.min.-1] 0 (-4 to 4)% [0 (-0.3 to 0.3) L.min.-1]); b) error per-
centage: 29% (20-37), 30% (24-37). The difference between 
CI measurements by TD and G2 were strongly correlated with 
the total systemic vascular resistance (r2 = 0.37, p < 0.0001) 
and weakly correlated with G3 (r2 = 0.05). In conclusion, the 
third generation FloTrac is more accurate and less inﬂ uenced 
by total systemic vascular resistance (SVR) than the second 
generation.
Recommendations: The measurements obtained by the 
FloTrac/Vigileo system have low correlation, high percentage 
of disagreement, signiﬁ cant bias, and wide limits of agree-
ment compared to cardiac output invasive measurements.
The authors recommended that the cardiac output mo-
nitoring by uncalibrated pulse wave analysis not be used in 
septic patients (A).
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